ProMIS Neurosciences raises up to $175M in PIPE; extends cash runway into 2028

ProMIS Neurosciences Inc.

Upfront gross proceeds ~$75M from ~6.8M common shares and 100K pre-funded warrants; up to ~$100M more from warrant exercise.
Pricing: common shares at $10.77 (most) and $12.13 for insiders; warrants exercisable at $14.40.
Warrants expire 60 days after PMN310 SAD topline data announcement or Feb 3, 2031.
Proceeds to fund Phase 1b Alzheimer's study and subcutaneous PMN310 development; blinded 6-month data expected mid-2026.
Co-led by Janus Henderson and Ally Bridge Group; CEO and board also participated.

item 1.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ProMIS Neurosciences Inc. entered into Registration Rights Agreement with each of the PIPE Investors.

Action: entry
Agreement: equity purchase
Counterparty: each of the PIPE Investors

Exact text from the filing

In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with each of the PIPE Investors (the “ Registration Rights Agreement ”), pursuant to which the Company is required to prepare and file a registration statement (the “ Registration Statement ”) with the Securities and Exchange Commission (the “ SEC ”) under the Securities Act, covering the resale of the Common Shares issued to the PIPE Investors under the Securities Purchase Agreement, together with the Warrant Shares.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ProMIS Neurosciences Inc. entered into Securities Purchase Agreement with selected investors that qualify as "accredited investors" valued at approximately $75 million (effective 2026-01-29).

Action: entry
Agreement: equity purchase
Counterparty: selected investors that qualify as "accredited investors"
Value: approximately $75 million
Effective: 2026-01-29

Exact text from the filing

On January 29, 2026, ProMIS Neurosciences Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with selected investors that qualify as “accredited investors” (the “ PIPE Investors ”), as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended (the “ Securities Act ”), for the purpose of raising approximately $75 million in aggregate gross proceeds for the Company (the “ Offering ”) before deducting placement agent fees and other expenses payable by the Company.

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-008325

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.